Inhibikase Therapeutics (IKT) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $1.83, +1.67% vs the prior close of $1.80.
- Volume 400.70K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IKT rises 1.7% to $1.83. Closed at $1.83, +1.67% vs the prior close of $1.80. Day range $1.79–$1.87, opened at $1.80.
IKT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — IKT rises 1.7% to $1.83
- Closed at $1.83, +1.67% vs the prior close of $1.80. Day range $1.79–$1.87, opened at $1.80.
- Volume was 400.70K shares, 0.7x its 50-day average of 541.70K.
- Price is -18.7% vs its 50-day average ($2.25) and -6.1% vs its 200-day average ($1.95).
- 52-week range $1.33–$2.61; today's close sits at 39% of that range, 29.9% below the 52-week high.
Oct 14, 2026 — IKT rises 2.3% to $1.80 on 2.9x normal volume
- Closed at $1.80, +2.27% vs the prior close of $1.76. Day range $1.72–$1.87, opened at $1.73.
- Volume was 1.58M shares, 2.9x its 50-day average of 535.23K — unusually heavy trading.
- Price is -20.5% vs its 50-day average ($2.26) and -7.7% vs its 200-day average ($1.95).
- 52-week range $1.33–$2.61; today's close sits at 37% of that range, 31.0% below the 52-week high.
Oct 13, 2026 — IKT slides 4.6% to $1.76, a 3-month low on 2.2x normal volume
- Closed at $1.76, -4.61% vs the prior close of $1.85. Day range $1.73–$1.88, opened at $1.85.
- Volume was 1.16M shares, 2.2x its 50-day average of 521.67K — unusually heavy trading.
- Price is -22.7% vs its 50-day average ($2.28) and -9.8% vs its 200-day average ($1.95).
- 52-week range $1.33–$2.61; today's close sits at 34% of that range, 32.6% below the 52-week high.
Oct 12, 2026 — IKT slides 6.3% to $1.85, a 3-month low
- Closed at $1.85, -6.35% vs the prior close of $1.97. Day range $1.77–$1.95, opened at $1.95.
- Volume was 741.40K shares, 1.4x its 50-day average of 514.23K.
- Price is -19.3% vs its 50-day average ($2.29) and -5.4% vs its 200-day average ($1.95).
- 52-week range $1.33–$2.61; today's close sits at 40% of that range, 29.3% below the 52-week high.
Oct 9, 2026 — IKT jumps 3.1% to $1.97
- Closed at $1.97, +3.14% vs the prior close of $1.91. Day range $1.87–$1.98, opened at $1.90.
- Volume was 435.00K shares, 0.8x its 50-day average of 513.58K.
- Price is -14.0% vs its 50-day average ($2.29) and +1.1% vs its 200-day average ($1.95).
- 52-week range $1.33–$2.61; today's close sits at 50% of that range, 24.5% below the 52-week high.
Oct 8, 2026 — IKT dips 1.5% to $1.91, a 3-month low, 4 down days in a row
- Closed at $1.91, -1.55% vs the prior close of $1.94. Day range $1.86–$1.94, opened at $1.94.
- Volume was 417.30K shares, 0.8x its 50-day average of 518.93K.
- Price is -16.9% vs its 50-day average ($2.30) and -1.9% vs its 200-day average ($1.95).
- 52-week range $1.33–$2.61; today's close sits at 45% of that range, 26.8% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — IKT dips 2.0% to $1.94, 3 down days in a row
- Closed at $1.94, -2.02% vs the prior close of $1.98. Day range $1.92–$2.00, opened at $1.95.
- Volume was 444.00K shares, 0.9x its 50-day average of 519.49K.
- Price is -15.8% vs its 50-day average ($2.30) and -0.3% vs its 200-day average ($1.95).
- 52-week range $1.33–$2.61; today's close sits at 48% of that range, 25.7% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — IKT dips 1.0% to $1.98
- Closed at $1.98, -1.00% vs the prior close of $2.00. Day range $1.95–$2.04, opened at $1.97.
- Volume was 583.80K shares, 1.1x its 50-day average of 518.09K.
- Price is -14.3% vs its 50-day average ($2.31) and +1.8% vs its 200-day average ($1.95).
- 52-week range $1.33–$2.61; today's close sits at 51% of that range, 24.1% below the 52-week high.
Oct 5, 2026 — IKT ends flat (+0.0%) to $2.00
- Closed at $2.00, +0.00% vs the prior close of $2.00. Day range $1.96–$2.03, opened at $2.00.
- Volume was 407.30K shares, 0.7x its 50-day average of 553.11K.
- Price is -13.8% vs its 50-day average ($2.32) and +2.9% vs its 200-day average ($1.94).
- 52-week range $1.33–$2.61; today's close sits at 52% of that range, 23.4% below the 52-week high.
Oct 2, 2026 — IKT jumps 3.6% to $2.00
- Closed at $2.00, +3.63% vs the prior close of $1.93. Day range $1.93–$2.02, opened at $1.96.
- Volume was 434.50K shares, 0.8x its 50-day average of 571.38K.
- Price is -14.0% vs its 50-day average ($2.33) and +3.0% vs its 200-day average ($1.94).
- 52-week range $1.33–$2.61; today's close sits at 52% of that range, 23.4% below the 52-week high.
IKT latest news & SEC filings
Every SEC filing by or about IKT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 4.01 — Changed its outside auditor.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $0)
- Net income: -$19.59M (prior year -$9.92M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.11 (prior year -$0.11) ( vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 31, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.02 — Sold unregistered shares.
Jul 28, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 17, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Things to know before you trade IKT
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 26, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.82% (largest 6.9%).
- Liquidity: about 711.50K shares (≈$1.30M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.83 vs a range of $1.33–$2.61 (39% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 3 open-market buys, 0 sales; latest: Frank M. Sands bought 2,068,965 shares on Nov 21, 2025.
- Latest filings: 8-K Sep 8, 2026; 8-K Aug 26, 2026; 10-Q Aug 11, 2026.
- Share count: 139.54M shares outstanding (Aug 4, 2026), +87.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
IKT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 1.80 | 1.87 | 1.79 | 1.83 | 400.70K |
| Oct 14, 2026 | 1.73 | 1.87 | 1.72 | 1.80 | 1.58M |
| Oct 13, 2026 | 1.85 | 1.88 | 1.73 | 1.76 | 1.16M |
| Oct 12, 2026 | 1.95 | 1.95 | 1.77 | 1.85 | 741.40K |
| Oct 9, 2026 | 1.90 | 1.98 | 1.87 | 1.97 | 435.00K |
| Oct 8, 2026 | 1.94 | 1.94 | 1.86 | 1.91 | 417.30K |
| Oct 7, 2026 | 1.95 | 2.00 | 1.92 | 1.94 | 444.00K |
| Oct 6, 2026 | 1.97 | 2.04 | 1.95 | 1.98 | 583.80K |
| Oct 5, 2026 | 2.00 | 2.03 | 1.96 | 2.00 | 407.30K |
| Oct 2, 2026 | 1.96 | 2.02 | 1.93 | 2.00 | 434.50K |
| Oct 1, 2026 | 2.10 | 2.10 | 1.93 | 1.93 | 474.70K |
| Sep 30, 2026 | 2.03 | 2.08 | 1.99 | 2.06 | 579.50K |
| Sep 29, 2026 | 2.03 | 2.05 | 2.01 | 2.02 | 400.30K |
| Sep 28, 2026 | 2.05 | 2.07 | 1.94 | 2.05 | 765.10K |
| Sep 25, 2026 | 2.10 | 2.15 | 2.05 | 2.06 | 447.20K |
| Sep 24, 2026 | 2.15 | 2.17 | 2.08 | 2.10 | 499.10K |
| Sep 23, 2026 | 2.30 | 2.31 | 2.14 | 2.15 | 412.30K |
| Sep 22, 2026 | 2.23 | 2.34 | 2.21 | 2.31 | 468.70K |
| Sep 21, 2026 | 2.31 | 2.32 | 2.19 | 2.20 | 366.00K |
| Sep 18, 2026 | 2.31 | 2.35 | 2.28 | 2.30 | 3.21M |
About Inhibikase Therapeutics
Inhibikase Therapeutics (IKT) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in WILMINGTON, DE. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1750149.
IKT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Vincent Aurentz | Director | Jun 30, 2026 |
| Dennis N Berman | Director | Jul 31, 2026 |
| Roberto Bellini | Director | Jun 30, 2026 |
| David Canner | Director | Jun 30, 2026 |
| Mark T Iwicki | Chief Executive Officer | Jan 7, 2026 |
| Arvind Kush | Director | Jun 30, 2026 |
| Amit Munshi | Director | Jun 30, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christopher Cabell | President & Head of R&D | Feb 24, 2026 |
| Mark T Iwicki | Chief Executive Officer | Jan 7, 2026 |
| David Mcintyre | Chief Financial Officer | Jan 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Nov 21, 2025 | Frank M. Sands | Buy | 2,068,965 | $1.45 |
| Nov 21, 2025 | Capital Life Sciences Pulse Fund Ii, L.P. Sands | Buy | 2,068,965 | $1.45 |
| Nov 21, 2025 | Capital Alternatives, Llc Sands | Buy | 2,068,965 | $1.45 |
IKT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-48.26M | -0.49 | $-27.79M |
| Dec 31, 2024 | $0 | $-27.52M | -1.16 | $-19.15M |
| Dec 31, 2023 | $260.50K | $-19.03M | -3.16 | $-18.09M |
| Dec 31, 2022 | $123.44K | $-18.05M | -4.28 | $-17.35M |
| Dec 31, 2021 | $3.10M | $-14.79M | -0.81 | $-14.30M |
Latest balance sheet: total assets $163.59M, total liabilities $10.26M, cash $178.80M (as of Jun 30, 2026).
IKT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $2.45 |
| May 12, 2026 | 8-K Item 2.02 (results) | $1.92 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $1.63 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $1.53 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $1.71 |
| May 14, 2025 | 8-K Item 2.02 (results) | $2.12 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $2.37 |
| Nov 17, 2022 | 8-K Item 2.02 (results) | — |
| Apr 1, 2021 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on IKT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.